1. Home
  2. CMMB
  3. CMMB News

Latest Chemomab Therapeutics Ltd. (CMMB) News on December 23, 2024

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
CMMB

GlobeNewswire

20 days ago

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
CMMB

GlobeNewswire

a month ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
CMMB

GlobeNewswire

a month ago

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
CMMB

GlobeNewswire

2 months ago

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
CMMB

GlobeNewswire

2 months ago

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Present at October 2024 Investor Conferences
CMMB

GlobeNewswire

3 months ago

Chemomab Therapeutics to Present at October 2024 Investor Conferences

Chemomab Therapeutics to Present at September 2024 Investor Conferences
CMMB

GlobeNewswire

4 months ago

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
CMMB

GlobeNewswire

4 months ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
CMMB

GlobeNewswire

4 months ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Closing of $10 Million Private Placement
CMMB

GlobeNewswire

5 months ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
CMMB

GlobeNewswire

5 months ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Chemomab Therapeutics Announces $10 Million Private Placement
CMMB

GlobeNewswire

5 months ago

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
CMMB

GlobeNewswire

5 months ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
CMMB

GlobeNewswire

6 months ago

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
CMMB

GlobeNewswire

7 months ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
CMMB

GlobeNewswire

7 months ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
CMMB

GlobeNewswire

7 months ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
CMMB

GlobeNewswire

7 months ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
CMMB

GlobeNewswire

8 months ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
CMMB

GlobeNewswire

8 months ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
CMMB

GlobeNewswire

8 months ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
CMMB

GlobeNewswire

9 months ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
CMMB

GlobeNewswire

9 months ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
CMMB

PR Newswire

10 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
CMMB

PR Newswire

10 months ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
CMMB

PR Newswire

10 months ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
CMMB

PR Newswire

10 months ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Participate in Upcoming Investor Conferences
CMMB

PR Newswire

a year ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

AG Mortgage Investment Trust, Inc. Announces Tax Treatment of 2023 Distributions
CMMB

Business Wire

a year ago

AG Mortgage Investment Trust, Inc. Announces Tax Treatment of 2023 Distributions

Janover Named 2024 Commercial Real Estate Tech Influencer by GlobeSt.com
CMMB

GlobeNewswire

a year ago

Janover Named 2024 Commercial Real Estate Tech Influencer by GlobeSt.com

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
CMMB

PR Newswire

a year ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

LENSAR Decline Means Insider Profits Down To US$42k
CMMB

Simply Wall St.

a year ago

LENSAR Decline Means Insider Profits Down To US$42k

D-Wave Joins Forces with Deloitte Canada to Advance Quantum Adoption
CMMB

Business Wire

a year ago

D-Wave Joins Forces with Deloitte Canada to Advance Quantum Adoption

Ronny Yakov Bought 17% More Shares In OLB Group
CMMB

Simply Wall St.

a year ago

Ronny Yakov Bought 17% More Shares In OLB Group

Calculating The Intrinsic Value Of Rent the Runway, Inc. (NASDAQ:RENT)
CMMB

Simply Wall St.

a year ago

Calculating The Intrinsic Value Of Rent the Runway, Inc. (NASDAQ:RENT)

Alaska credit union to buy $1.5B-asset Washington bank
CMMB

Banking Dive

a year ago

Alaska credit union to buy $1.5B-asset Washington bank

Trust Stamp ® Announces that Forty-Five customers started or completed integration with the Company’s Orchestration Layer by the end of 2023
CMMB

GlobeNewswire

a year ago

Trust Stamp ® Announces that Forty-Five customers started or completed integration with the Company’s Orchestration Layer by the end of 2023

Ohmyhome and Webuy Announce Strategic Collaboration to Cross-Sell Products and Services Across Singapore
CMMB

GlobeNewswire

a year ago

Ohmyhome and Webuy Announce Strategic Collaboration to Cross-Sell Products and Services Across Singapore

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
CMMB

GlobeNewswire

a year ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
CMMB

GlobeNewswire

a year ago

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
CMMB

PR Newswire

a year ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

WANG & LEE GROUP First Half 2023 Earnings: US$0.11 loss per share (vs US$0.032 loss in 1H 2022)
CMMB

Simply Wall St.

a year ago

WANG & LEE GROUP First Half 2023 Earnings: US$0.11 loss per share (vs US$0.032 loss in 1H 2022)

Bright Scholar Filed Annual Report on Form 20-F for Fiscal 2023
CMMB

PR Newswire

a year ago

Bright Scholar Filed Annual Report on Form 20-F for Fiscal 2023

CMMB

Business Wire

a year ago

SIFCO Industries, Inc. ("SIFCO") Announces Fourth Quarter and Full Year Fiscal 2023 Financial Results

Royce Global Value Trust (NYSE: RGT) as of Nov 30, 2023
CMMB

PR Newswire

a year ago

Royce Global Value Trust (NYSE: RGT) as of Nov 30, 2023

Bright Scholar Announces Results of 2024 Annual General Meeting
CMMB

PR Newswire

a year ago

Bright Scholar Announces Results of 2024 Annual General Meeting

Movano Health Announces HSA/FSA Eligibility for its Women First Wearable, The Evie Ring
CMMB

PR Newswire

a year ago

Movano Health Announces HSA/FSA Eligibility for its Women First Wearable, The Evie Ring

One Hennessy Advisors Insider Raised Their Stake In The Previous Year
CMMB

Simply Wall St.

a year ago

One Hennessy Advisors Insider Raised Their Stake In The Previous Year

CMMB

Associated Press Finance

a year ago

Enzo Biochem: Fiscal Q1 Earnings Snapshot

ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
CMMB

GlobeNewswire

a year ago

ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

Is There An Opportunity With Traeger, Inc.'s (NYSE:COOK) 45% Undervaluation?
CMMB

Simply Wall St.

a year ago

Is There An Opportunity With Traeger, Inc.'s (NYSE:COOK) 45% Undervaluation?

MARPAI, INC. ANNOUNCES APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS
CMMB

PR Newswire

a year ago

MARPAI, INC. ANNOUNCES APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS

SYLA Technologies Updates 2023 Full Year Financial Guidance with Upward Revision of Income from Continuing Operations and Earnings Per Share
CMMB

GlobeNewswire

a year ago

SYLA Technologies Updates 2023 Full Year Financial Guidance with Upward Revision of Income from Continuing Operations and Earnings Per Share

Blackboxstocks, Inc. Signs Definitive Agreement to Acquire Evtec Aluminium, Supplier of Proprietary Parts for the EV, Hybrid, and Performance Automotive Market, with Projected Revenue of US$52 Million for Fiscal Year Ending June 30, 2024
CMMB

Business Wire

a year ago

Blackboxstocks, Inc. Signs Definitive Agreement to Acquire Evtec Aluminium, Supplier of Proprietary Parts for the EV, Hybrid, and Performance Automotive Market, with Projected Revenue of US$52 Million for Fiscal Year Ending June 30, 2024

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)
CMMB

Simply Wall St.

a year ago

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)

17 Education & Technology Group Inc. Announces Third Quarter 2023 Unaudited Financial Results
CMMB

GlobeNewswire

a year ago

17 Education & Technology Group Inc. Announces Third Quarter 2023 Unaudited Financial Results

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
CMMB

GlobeNewswire

a year ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Express, Inc. (NYSE:EXPR) Q3 2023 Earnings Call Transcript
CMMB

Insider Monkey

a year ago

Express, Inc. (NYSE:EXPR) Q3 2023 Earnings Call Transcript

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to January 3, 2024
CMMB

GlobeNewswire

a year ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to January 3, 2024

Deion "Coach Prime" Sanders Named 2023 Sports Illustrated Sportsperson of the Year
CMMB

Business Wire

a year ago

Deion "Coach Prime" Sanders Named 2023 Sports Illustrated Sportsperson of the Year

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
CMMB

ACCESSWIRE

a year ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Inseego Appoints SVP of Global Channel Sales and Distribution
CMMB

Business Wire

a year ago

Inseego Appoints SVP of Global Channel Sales and Distribution

CMMB

Business Wire

a year ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

CVG Announces Participation in the NobleCon19 Investor Conference
CMMB

GlobeNewswire

a year ago

CVG Announces Participation in the NobleCon19 Investor Conference

CMMB

Business Wire

a year ago

ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference

Returns On Capital Are Showing Encouraging Signs At NL Industries (NYSE:NL)
CMMB

Simply Wall St.

a year ago

Returns On Capital Are Showing Encouraging Signs At NL Industries (NYSE:NL)

Director Michael Thompson's Strategic Insider Purchase of AuthID Inc Shares
CMMB

GuruFocus.com

a year ago

Director Michael Thompson's Strategic Insider Purchase of AuthID Inc Shares

Cineverse Inks Global Commercial YouTube Channel Agreement with Little Dot Studios
CMMB

PR Newswire

a year ago

Cineverse Inks Global Commercial YouTube Channel Agreement with Little Dot Studios

authID Inc. Announces Pricing of Approximately $9.4 Million Registered Direct Offering
CMMB

GlobeNewswire

a year ago

authID Inc. Announces Pricing of Approximately $9.4 Million Registered Direct Offering

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
CMMB

PR Newswire

a year ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q3 2023 Earnings Call Transcript
CMMB

Insider Monkey

a year ago

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q3 2023 Earnings Call Transcript

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
CMMB

PR Newswire

a year ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

CMMB

Associated Press Finance

a year ago

Northern Dynasty: Q3 Earnings Snapshot

Castellum, Inc. Announces Third Quarter Financial Results
CMMB

GlobeNewswire

a year ago

Castellum, Inc. Announces Third Quarter Financial Results

Sonida Senior Living, Inc. Announces Third Quarter 2023 Results
CMMB

Business Wire

a year ago

Sonida Senior Living, Inc. Announces Third Quarter 2023 Results

Northern Dynasty Receives Initial Advance under Second Tranche of Amended Royalty Agreement
CMMB

ACCESSWIRE

a year ago

Northern Dynasty Receives Initial Advance under Second Tranche of Amended Royalty Agreement

Squatty Potty Re-Launches In Walmart Stores Nationwide
CMMB

GlobeNewswire

a year ago

Squatty Potty Re-Launches In Walmart Stores Nationwide

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
CMMB

PR Newswire

a year ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Bearish: Analysts Just Cut Their Smith Micro Software, Inc. (NASDAQ:SMSI) Revenue and EPS estimates
CMMB

Simply Wall St.

a year ago

Bearish: Analysts Just Cut Their Smith Micro Software, Inc. (NASDAQ:SMSI) Revenue and EPS estimates

CMMB

Associated Press Finance

a year ago

Almaden Minerals: Q3 Earnings Snapshot

Caliber Reports Third Quarter 2023 Results
CMMB

Business Wire

a year ago

Caliber Reports Third Quarter 2023 Results

urban-gro, Inc. Reports Third Quarter 2023 Financial Results Demonstrating Sequential Improvement in Revenue, Backlog, and Adjusted EBITDA
CMMB

GlobeNewswire

a year ago

urban-gro, Inc. Reports Third Quarter 2023 Financial Results Demonstrating Sequential Improvement in Revenue, Backlog, and Adjusted EBITDA

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
CMMB

PR Newswire

a year ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
CMMB

PR Newswire

a year ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Share on Social Networks: